Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC73424 structure
    GC73424PRT062607 acetate
    CAS: 1370261-98-5
    纯度: >99.00%

    PRT062607 acetate是一种口服Syk抑制剂(IC50: 1 nM),可抑制炎症和诱导细胞凋亡。

  • GC73428 structure
    GC73428CWI1-2 hydrochloride
    CAS: 2408590-37-2
    纯度: >98.00%

    CWI1-2 hydrochloride是一种结合IGF2BP2并抑制其与m6A修饰的靶转录物相互作用、诱导凋亡和分化的IGF2BP2抑制剂。

  • GC73441 structure
    GC73441EAPB 02303
    CAS: 1958290-51-1
    纯度: >99.00%

    EAPB 02303是一种微管破坏剂和抑制剂。

  • GC73469 structure
    GC73469Cereblon inhibitor 2
    CAS: 2639380-62-2
    纯度: >98.00%

    Cereblon inhibitor 2(化合物8)是一种Cereblon抑制剂,在实体肿瘤研究中非常有用,尤其是乳腺癌。

  • GC73476 structure
    GC73476MYC-RIBOTAC
    纯度: >98.00%

    MYC-RIBOTAC是一个靶向MYC内部核糖体进入位点(IRES)的核糖核酸酶嵌合体(RIBOTAC)。

  • GC73491 structure
    GC73491RapaBlock
    CAS: 2474076-02-1
    纯度: >98.00%

    RapaBlock是一种强效、非免疫抑制和脑不可渗透的FKBP12配体。

  • GC73501 structure
    GC73501Wu-5
    CAS: 2630378-05-9
    纯度: >98.00%

    Wu-5是一种USP10抑制剂,可以抑制FLT3和AMPK通路,诱导FLT3-ITD降解并诱导细胞凋亡。

  • GC73541 structure
    GC73541PRMT5-IN-31
    纯度: >99.00%

    PRMT5-IN-31(化合物3m)是一种选择性PRMT5抑制剂(IC50: 0.31 μM)。

  • GC73543 structure
    GC73543FC-116
    CAS: 2417298-29-2
    纯度: >98.00%

    FC-116是一种有效抑制小鼠肿瘤生长的微管蛋白抑制剂。

  • GC73546 structure
    GC73546PD-L1-IN-3
    CAS: 2953044-29-4
    纯度: >99.00%

    PD-L1-IN-3 (Compound 4a)是一种靶向PD-1/PD-L1的化合物,其抑制PD-L1和Jurkat T细胞的IC50值和EC50值分别为4.97nM和2.70 μM。

  • GC73549 structure
    GC73549LSD1-IN-27
    CAS: 2904571-94-2
    纯度: >98.00%

    LSD1-IN-27(化合物5ac)是LSD1抑制剂(IC50:13nM)。

  • GC73555 structure
    GC73555PI3Kδ-IN-16
    CAS: 2766437-35-6
    纯度: >99.00%

    PI3Kδ-IN-16是PI3Kδ的强效选择性抑制剂。

  • GC73561 structure
    GC73561YS-363
    CAS: 2470908-90-6
    纯度: >99.00%

    YS-363是一种强效、选择性和口服活性的EGFR抑制剂,野生型和L858R突变型EGFR的IC50分别为0.96 nM和0.67 nM。

  • GC73567 structure
    GC73567Os30
    CAS: 2998928-68-8
    纯度: >98.00%

    Os30是一种强效的第四代EGFR抑制剂,是一种有效的EGFRC797S-TK抑制剂,对EGFRDel19/T790M/C797S TK和EGFRL858R/T790M/C797S TK的IC50值分别为18 nM和113 nM。

  • GC73569 structure
    GC73569MY-1076
    CAS: 3008262-76-5
    纯度: >99.00%

    MY-1076是YAP的抑制剂。

  • GC73571 structure
    GC73571Tubulin polymerization-IN-56
    CAS: 2966790-98-5
    纯度: >99.00%

    Tubulin polymerization-IN-56吲唑衍生物是一种强效的微管蛋白聚合抑制剂,通过与秋水仙素位点相互作用,导致细胞周期阻滞和细胞凋亡。

  • GC73572 structure
    GC73572PP5-IN-1
    CAS: 1022417-69-1
    纯度: >99.00%

    PP5-IN-1(化合物P053)是一种丝氨酸/苏氨酸蛋白磷酸酶-5 (PP5)的竞争性抑制剂,结合其催化结构域并导致肾癌细胞凋亡。

  • GC73579 structure
    GC73579DDO-2728
    CAS: 3029515-97-4
    纯度: >98.00%

    DDO-2728(化合物19)是一种选择性AlkB同源物5(ALKBH5)抑制剂,IC50为2.97μM。

  • GC73585 structure
    GC73585(Rac)-M826
    CAS: 2649883-37-2
    纯度: 不显示

    (Rac)-M826是M826的外消旋体。

  • GC73594 structure
    GC73594KH16
    纯度: >98.00%

    KH16是一种有效的低纳摩尔HDAC抑制剂。

  • GC73599 structure
    GC73599TH9619
    CAS: 2379556-22-4
    纯度: >99.00%

    TH9619是MTHFD1和MTHFD2中去磷酸根酶和环磷酸根酶活性的有效抑制剂,IC50值为47nM,并选择性杀死癌症细胞。

  • GC73601 structure
    GC73601UCM-1336
    CAS: 1621535-90-7
    纯度: >99.00%

    UCM-1336是一种有效的ICMT抑制剂,IC50为2μM。

  • GC73604 structure
    GC73604MeOIstPyrd
    CAS: 2308548-54-9
    纯度: >99.00%

    MeOIstPyrd是一种抗皮肤癌症剂。

  • GC73619 structure
    GC73619M190S
    CAS: 2578300-07-7
    纯度: >99.00%

    M190S是一种新型小分子,在体外和体内保护细胞免受线粒体依赖性凋亡。